Back to Search
Start Over
Adjuvant therapy in pancreatic cancer.
- Source :
-
World journal of gastroenterology [World J Gastroenterol] 2014 Oct 28; Vol. 20 (40), pp. 14733-46. - Publication Year :
- 2014
-
Abstract
- Pancreatic cancer remains one of the leading causes of cancer related death worldwide with an overall five-year survival of less than 5%. Potentially curative surgery, which alone can improve 5-year survival to 10%, is an option for only 10%-20% of patients at presentation owing to local invasion of the tumour or metastatic disease. Adjuvant chemotherapy has been shown to improve 5-year survival to 20%-25% but conflicting evidence remains with regards to chemoradiation. In this article we review the current evidence available from published randomised trials and discuss ongoing phase III trials in relation to adjuvant therapy in pancreatic cancer.
- Subjects :
- Carcinoma, Pancreatic Ductal mortality
Carcinoma, Pancreatic Ductal pathology
Chemoradiotherapy, Adjuvant
Chemotherapy, Adjuvant
Clinical Trials, Phase III as Topic
Evidence-Based Medicine
Humans
Neoplasm Staging
Pancreatic Neoplasms mortality
Pancreatic Neoplasms pathology
Treatment Outcome
Carcinoma, Pancreatic Ductal therapy
Pancreatic Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2219-2840
- Volume :
- 20
- Issue :
- 40
- Database :
- MEDLINE
- Journal :
- World journal of gastroenterology
- Publication Type :
- Academic Journal
- Accession number :
- 25356036
- Full Text :
- https://doi.org/10.3748/wjg.v20.i40.14733